ImmuPharma plc (LON:IMM – Get Free Report) fell 14.6% during mid-day trading on Wednesday . The stock traded as low as GBX 3.20 ($0.04) and last traded at GBX 3.20 ($0.04). 13,200,714 shares changed hands during trading, a decline of 53% from the average session volume of 28,314,303 shares. The stock had previously closed at GBX 3.75 ($0.05).
ImmuPharma Stock Performance
The company has a 50-day simple moving average of GBX 1.48 and a 200-day simple moving average of GBX 1.66. The company has a market cap of £12.44 million, a price-to-earnings ratio of -298.80 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- What is the NASDAQ Stock Exchange?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- 3 Small Caps With Big Return Potential
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Financial Services Stocks Investing
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
